Form 4: Madrigal Pharmaceuticals Executive Waltermire Reports Stock Option Exercises and Sales

Senior VP Robert E. Waltermire reports exercising stock options and selling shares of Madrigal Pharmaceuticals common stock on March 5, 2025.

Summary

• Robert E. Waltermire, Senior VP, Chief Pharma Dev. of Madrigal Pharmaceuticals, reported transactions involving the company's stock on March 5, 2025.
• Waltermire exercised stock options to acquire 6,825 shares at $87.92 and 7,288 shares at $87.09.
• He also sold a total of 11,113 shares in multiple transactions at prices ranging from $335.1459 to $344.757.
• Additionally, Waltermire was granted 2,061 restricted stock units that vest in installments starting March 5, 2026.
• Following these transactions, Waltermire directly owns 5,789 shares of common stock and derivative securities including options to buy 4,219 shares and 1,157 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document primarily reports transactions without expressing an opinion on the company's performance or future outlook. The stock sales are balanced by option exercises and the grant of restricted stock units.

Positives

• The exercise of stock options indicates confidence in the company's future performance, as the executive chose to convert these options into shares.
• The grant of restricted stock units aligns the executive's interests with those of the shareholders, as the vesting is contingent on continued service with the company.

Negatives

• The sale of 11,113 shares by the executive could be interpreted negatively by the market, although it may be part of a pre-planned diversification strategy.

Risks

• Executive stock sales can sometimes signal a lack of confidence in the company's future prospects, potentially impacting investor sentiment.
• The vesting schedule of the restricted stock units is dependent on the executive's continued employment, creating a potential risk if the executive were to leave the company.

Future Outlook

The executive's future holdings will be influenced by the vesting of restricted stock units and any further stock option exercises or sales.

Industry Context

Executive stock transactions are common in the pharmaceutical industry and are closely monitored by investors for insights into management's perspective on the company's prospects.

Comparison to Industry Standards

• Executive compensation packages in the pharmaceutical industry typically include a mix of salary, stock options, and restricted stock units.
• Vesting schedules for restricted stock units are often tied to performance metrics or continued employment, aligning executive interests with shareholder value.
• Stock option exercises and sales are a normal part of executive compensation and wealth management.

Stakeholder Impact

• Shareholders may react to the reported transactions, potentially influencing the stock price.
• Employees may view the executive's stock transactions as a signal of confidence or concern about the company's future.

Next Steps

• Monitor future filings by the reporting person for further transactions.
• Track the vesting of restricted stock units and any subsequent stock sales.

Key Dates